贝那普利联合黄葵对慢性肾小球肾炎的治疗效果及安全性评价

摘要

Objective:To study on the efficiency and safety of benazepril combined with Huangkui in the treatment process of chronic glomerulonephritis .Methods :The 96 patients with chronic glomerulonephritis were treated .They were divided into observation group (n = 48) and control group (n = 48) .The patients were treated with benazepril in the control group ,while the patients were treated with benazepril and Huangkui in the observation group .The treatment effects were observed and compared .Results :① Before treatment ,it was not significantly different in these two groups about urinary protein quantification and renal function (BUN ,Scr) ,plasma albumin and blood pressure (systolic blood pressure ,diastolic blood pressure) ,plasma albumin ,the levels of TC and TG , red blood cells and white blood cells in the urine (P>0 .05) ,but after treatment ,the indexes including urinary pro-tein quantification and renal function ,plasma albumin and blood pressure ,the levels of TC and TG ,red blood cells and white blood cells in the urine in the observation group was lower than that of the control group (P<0 .05) ,and plasma albumin was significantly higher than the control group (P<0 .05) .②The effective rate of the observation group was significantly higher than that of the control group (91 .67% VS 72 .92% , P<0 .05) .Besides ,the posi-tive rate of red blood cells and white blood cells in the urine was lower than that of the control group (P<0 .05) .③Before and after treatment ,there was no significant difference about the level of GPT between these two groups (P>0 .05) ,and there were fewer adverse reactions .Conclusion:Benazepril combined with Huangkui is used to chronic glomerulonephritis ,and it can significantly reduce proteinuria with improved renal function .The effect is safe and effective and this method is recommended in clinical .%目的:探讨贝那普利联合黄葵对慢性肾小球肾炎的治疗效果与安全性.方法:将96例慢性肾小球肾炎患者分为观察组与对照组.对照组48例患者使用贝那普利进行治疗,观察组48例患者使用贝那普利与黄葵联合进行治疗,观察并比较两组患者的治疗效果.结果:①治疗前,两组患者尿蛋白定量及肾功能(BUN、Scr)、血浆白蛋白及血压(收缩压、舒张压)、血浆白蛋白、TC及TG水平、尿液中红细胞与白细胞数无统计学差异(P>0.05),而在治疗后,观察组患者尿蛋白定量及肾功能、血压值、TC与TG水平、尿液中红细胞及白细胞数明显低于对照组(P<0.05),而血浆白蛋白明显高于对照组(P<0.05);②观察组患者治疗有效率为91.67%,明显高于对照组的72.92%(P<0.05),且尿液中红细胞、白细胞阳性率明显低于对照组(P<0.05);③治疗前、后,两组患者GPT水平均无明显差别(P>0.05),且发生不良反应少.结论:贝那普利联合黄葵治疗慢性肾小球肾炎,降低患者蛋白尿,改善患者肾功能,疗效显著,安全可靠.